← All trials
NCT04864743
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 22, 2021
- Primary completion
- Apr 30, 2022
- Completion date
- Jul 30, 2022
- First posted
- Apr 29, 2021
- Last posted
- Jul 14, 2021
- Enrollment
- 18
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiangsu Gensciences lnc.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.